期刊文献+

离子对RP-HPLC法测定甲磺酸帕珠沙星尿药浓度 被引量:6

Determination of Pazufloxacin in Human Urine by Ion-pair RP-HPLC
暂未订购
导出
摘要 目的:建立反相离子对高效液相色谱法以测定尿液中帕珠沙星浓度。方法:色谱条件:Kromasil C18柱(250mm×4.6mm,5μm);流动相:3mmol/L十二烷基硫酸钠(含0.5%三乙胺,用H3PO4调pH至4.0)-乙腈(62:38,V/V);流速:1.0mL/min;紫外检测波长:242nm。结果:尿液标准曲线线性范围为1-300mg/L(r=0.9998),高、中、低三种浓度的批内和批间精密度均小于10.0%,提取回收率为94.0%-95.3%。12名健康志愿者分别进行单剂量静脉滴注注射用甲磺酸帕珠沙星后,帕珠沙星在24小时内尿液中的累积尿药排泄率为(90.3±2.6)%。结论:本方法准确可靠,操作简便,适用于临床药代动力学及常规尿药浓度监测。 Objective: To develop a method for the determination of Pazufloxacin concentration in human urine. Methods: Separation was performed on Kromasil C18 capillary column (250 mm× 4.6 mm, 5 μm). The mobile phase consisted of 3 mmol/L sodium dodecylsulphate (containing 0.5 % triethylamine and adjusted to pH 4.0 with phosphoric acid)-acetonitrile (62:38, V/V). The flow rate was 1.0 mL/min. The UV detection wavelength was at 242 nm. Results: A good linearity was obtained in the range of 1 - 300 mg/L with r = 0. 9998. The RSD of within-batch and between-batch variation of the method were both less than 10.0 %. The recoveries of three concentrations 1, 30, 300 mg/L were 94.0% - 95.3%. After being given an iv. administration of a single dose of Pazufloxacin rnesilate, the accumulative urine excretion rate of 12 vollanteers during 24 hours was (90.3 ± 2.6)%. Conclusion: This RP-HPLC method is simple, sensitive and accurate. It is suitable for the pharmacokinetic study of Pazufloxacin mesilate and its routine monitoring in human urine.
出处 《药学进展》 CAS 2006年第2期81-83,共3页 Progress in Pharmaceutical Sciences
关键词 帕珠沙星 离子对色谱 累积尿药排泄率 Pazufloxacin Ion-pair chromatography Accumulative urine excretion rate
  • 相关文献

参考文献3

二级参考文献17

  • 1Hayakawa H,Fujimaki K,Shimizu Y ,et al.Metabolic fate of pazufloxacin mesilate in human and animals [J].Jpn J Chemother,1999;47(Supp1.1) :S81-S84.
  • 2Takei M, Fukuda H, Kishii R, et al. Target preference of 15 quinolone against staphy- lococcus aureus based on antibacterial activities and target inhibition[J]. Antimicrob Agents Chemother, 2001;45:3544.
  • 3Sugihara T, Yoshida T, Minagawa H, et al. Clinical study of pazufloxacin mesilate, a new quinolone antibacterial agent, in burn infections and tissue concentrations[J]. Jpn J Chemother, 2000;48:401.
  • 4Tsurumaki Y, Manda H, Takei M, et al. In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from respiration tract, urinary tract and surgical infections during 1997-1998 in Japan[J]. Antimicrob Chemother, 2002;45(5):685-689.
  • 5Fung Tomc J, Minassian B, Kolek B, et al. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin[J]. Antimicrob Chemother, 2002;45(4):437-440.
  • 6Tanimura H, Uchiyama K, Endo S, et al. Clinical investigation and tissue concentrations of injectable pazufloxacin mesilate in patients with surgical infections[J]. Jpn J Chemother, 2000;48:353.
  • 7湖景哲雄 出町久美子 坪川畅子.(—)—(s)—10—(1—Aminocy—clopropyl)—9—fluoro—3—methyl—7—oxo—2,3—dihydro—7H—pyr—ido[1,2,3—de][1,4]benzoxazine—6—carboxylic acid (T—3761)化学构造及物理化学的性质[J].医药品研究,1995,26(4):211-222.
  • 8Nakashima M, Uemura K, Kosuge K, et al. Phase I clinical study of pazufloxacin mesilate[J]. Jpn J Chemother, 1999;47(Suppl 1):141.
  • 9Hayakawa H, Fujimaki K, Shimizu Y, et al. Metabolic fate of pazufloxacin mesilate in humans and animals[J]. Jpn J Chemother, 1999;47(Suppl 1):81.
  • 10Shimada K, Abe S, Fujishima T, et al. Clinical evaluation of Pazufloxacin mesilate for bacterial pneumonia[J]. Jpn J Chemother, 2000;48:433.

共引文献23

同被引文献63

引证文献6

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部